ArticleFood chemistry: X2026
Comparative enzymatic hydrolysis of porcine tracheal cartilage generates ACE/DPP-IV-inhibitory and antioxidant peptides with enhanced bioactivity following simulated gastrointestinal digestion and molecular docking analysis.
Article in Food chemistry: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine tracheal cartilage, an underutilized Type II collagen-rich by-product, was systematically evaluated as a source of angiotensin I-converting enzyme (ACE) inhibitory, dipeptidyl peptidase-IV (DPP-IV) inhibitory, and antioxidant peptides. Neutrase at 4 h outperformed Papain in generating ACE-inhibitory and antioxidant peptides. The <3 kDa ultrafiltration fraction, enriched in small hydrophobic peptides, exhibited the highest bioactivities. LC-MS/MS identified eight sequences (870-1565 Da). Chemical synthesis confirmed LGLGADMFHR as the most potent ACE inhibitor (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.